News & Events

Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial. O’Shaughnessy J, Petrakova K,… Ribociclib plus Letrozole

An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC). Awad MM, Chu… Phase II SCLC Study

The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma. Voss MH, Bhatt… The DART Study

Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Rugo HS, Seneviratne… Prevention of everolimus-related stomatitis

Managing Expectations in the Transition to Proof of Concept Studies. Kieber-Emmons T, Makhoul I, Pennisi A, Siegel ER, Emanuel PD, Monzavi-Karbassi B, Steplewski Z, Beck… Managing Expectations in the Transition to Proof of Concept Studies

The Role of Proteomic Testing in Improving Prognosis And Care Planning Quality Measures for Lung Cancer. Page RD, Argento AC, Nash DB, Skoufalos A, Schaefer… The Role of Proteomic Testing in Improving Prognosis And Care Planning Quality Measures for Lung Cancer

nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy. Thomas M, Spigel DR, Jotte RM, McCleod M, Socinski MA, Page RD, Gressot… Longitudinal quality of life while on chemotherapy

Financial Conflicts of Interest Among Oncology Clinical Pathway Vendors Daly B, Bach PB, Page RD. JAMA Oncol. 2017 Dec 21. doi: 10.1001/jamaoncol.2017.4473. [Epub ahead of… Financial Conflicts of Interest Among Oncology Clinical Pathway Vendors

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. BACKGROUND:The… Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS)